UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Effects of food and antacids on the pharmacokinetics of eltrombopag in healthy adult subjects: Two single-dose, open-label, randomized-sequence, crossover studies

Clinical therapeutics, 2009-04, Vol.31 (4), p.764-776

2009

Volltextzugriff (PDF)

Assessment of the Pharmacokinetic Interaction between Eltrombopag and Lopinavir-Ritonavir in Healthy Adult Subjects

Antimicrobial Agents and Chemotherapy, 2012-06, Vol.56 (6), p.2846-2851

2012

Volltextzugriff (PDF)

Modeling and Simulation Support Eltrombopag Dosing in Pediatric Patients With Immune Thrombocytopenia

Clinical pharmacology and therapeutics, 2018-12, Vol.104 (6), p.1199-1207

2018

Volltextzugriff (PDF)

Effect of Hepatic or Renal Impairment on Eltrombopag Pharmacokinetics

Journal of clinical pharmacology, 2011-05, Vol.51 (5), p.739-750

2011

Volltextzugriff (PDF)

Modeling and Simulation Support Eltrombopag Dosing in Thrombocytopenic Patients with Chronic HCV Infection

Pharmaceutical research, 2015-06, Vol.32 (6), p.2015-2028

2015

Volltextzugriff (PDF)

Population PK/PD Modeling of Eltrombopag in Healthy Volunteers and Patients With Immune Thrombocytopenic Purpura and Optimization of Response-Guided Dosing

Journal of clinical pharmacology, 2011-10, Vol.51 (10), p.1403-1417

2011

Volltextzugriff (PDF)

Effect of Antacids and Ranitidine on the Single-Dose Pharmacokinetics of Fosamprenavir

Antimicrobial Agents and Chemotherapy, 2005-01, Vol.49 (1), p.467-469

2005

Volltextzugriff (PDF)

Fosamprenavir plus Ritonavir Increases Plasma Ketoconazole and Ritonavir Exposure, while Amprenavir Exposure Remains Unchanged

Antimicrobial Agents and Chemotherapy, 2007-08, Vol.51 (8), p.2982-2984

2007

Volltextzugriff (PDF)

Ritonavir Increases Plasma Amprenavir (APV) Exposure to a Similar Extent when Coadministered with either Fosamprenavir or APV

Antimicrobial Agents and Chemotherapy, 2006-04, Vol.50 (4), p.1578-1580

2006

Volltextzugriff (PDF)

Novel 4,4-Disubstituted Piperidine-Based C–C Chemokine Receptor-5 Inhibitors with High Potency against Human Immunodeficiency Virus-1 and an Improved human Ether-a-go-go Related Gene (hERG) Profile

Journal of medicinal chemistry, 2011-06, Vol.54 (11), p.3756-3767

2011

Volltextzugriff (PDF)

Coadministration of esomeprazole with fosamprenavir has no impact on steady-state plasma amprenavir pharmacokinetics

Journal of acquired immune deficiency syndromes (1999), 2006-05, Vol.42 (1), p.61-67

2006

Volltextzugriff (PDF)

A Phase 1 Study To Evaluate Safety and Pharmacokinetics following Administration of Single and Multiple Doses of the Antistaphylococcal Lysin LSVT-1701 in Healthy Adult Subjects

Antimicrobial agents and chemotherapy, 2022-03, Vol.66 (3), p.e0184221-e0184221

2022

Volltextzugriff (PDF)

A Randomized, Open-Label, 5-Period, Balanced Crossover Study to Evaluate the Relative Bioavailability of Eltrombopag Powder for Oral Suspension (PfOS) and Tablet Formulations and the Effect of a High-Calcium Meal on Eltrombopag Pharmacokinetics When Administered With or 2 Hours Before or After PfOS

Clinical therapeutics, 2012-03, Vol.34 (3), p.699-709

2012

Volltextzugriff (PDF)

Phase I Safety and Pharmacokinetic Trials of 1263W94, a Novel Oral Anti-Human Cytomegalovirus Agent, in Healthy and Human Immunodeficiency Virus-Infected Subjects

Antimicrobial Agents and Chemotherapy, 2003-04, Vol.47 (4), p.1334-1342

2003

Volltextzugriff (PDF)

Phase I Dose Escalation Trial Evaluating the Pharmacokinetics, Anti-Human Cytomegalovirus (HCMV) Activity, and Safety of 1263W94 in Human Immunodeficiency Virus-Infected Men with Asymptomatic HCMV Shedding

Antimicrobial Agents and Chemotherapy, 2002-09, Vol.46 (9), p.2969-2976

2002

Volltextzugriff (PDF)

Fosamprenavir : Clinical pharmacokinetics and drug interactions of the amprenavir prodrug

Clinical pharmacokinetics, 2006-01, Vol.45 (2), p.137-168

2006

Volltextzugriff (PDF)

Six-Week Randomized Controlled Trial To Compare the Tolerabilities, Pharmacokinetics, and Antiviral Activities of GW433908 and Amprenavir in Human Immunodeficiency Virus Type 1-Infected Patients

Antimicrobial Agents and Chemotherapy, 2004-01, Vol.48 (1), p.116-123

2004

Volltextzugriff (PDF)

Pharmacokinetic and Safety Evaluation of High-Dose Combinations of Fosamprenavir and Ritonavir

Antimicrobial Agents and Chemotherapy, 2006-03, Vol.50 (3), p.928-934

2006

Volltextzugriff (PDF)

A 42-Week Open-Label Study to Assess the Pharmacokinetics, Antiretroviral Activity, and Safety of Amprenavir or Amprenavir plus Ritonavir in Combination with Abacavir and Lamivudine for Treatment of HIV-Infected Patients

Clinical infectious diseases, 2004-08, Vol.39 (4), p.591-594

2004

Volltextzugriff (PDF)

Fosamprenavir/ritonavir in advanced HIV disease (TRIAD): a randomized study of high-dose, dual-boosted or standard dose fosamprenavir/ritonavir in HIV-1-infected patients with antiretroviral resistance

Journal of antimicrobial chemotherapy, 2009-08, Vol.64 (2), p.398-410

2009

Volltextzugriff (PDF)

Pharmacokinetics and safety of GW433908 and ritonavir, with and without efavirenz, in healthy volunteers

AIDS (London), 2004-04, Vol.18 (6), p.897-907

2004

Volltextzugriff (PDF)

Pharmacokinetics and Pharmacodynamics of Methadone Enantiomers After Coadministration with Amprenavir in Opioid-Dependent Subjects

Pharmacotherapy, 2004-09, Vol.24 (9), p.1110-1121

2004

Volltextzugriff (PDF)

Reports of Committees

Bulletin of the American Library Association, 1909-09, Vol.3 (5), p.202-230

1909

Volltextzugriff (PDF)

1 – 23 von 23

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(22)
Mit Volltextzugriff
(20)

Publikationsform

Artikel
(23)

Sprache

Englisch
(23)

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(22)
Science & Technology
(22)
Humans
(21)
Adult
(19)
Pharmacology & Pharmacy
(19)
Male
(18)
Female
(15)
Biological And Medical Sciences
(14)
Medical Sciences
(14)
Middle Aged
(14)
Pharmacology. Drug Treatments
(13)
Antibiotics. Antiinfectious Agents. Antiparasitic Agents
(12)
Microbiology
(12)
Area Under Curve
(10)
Sulfonamides - Pharmacokinetics
(10)
Drug Interactions
(9)
Pharmacokinetics
(9)
Adolescent
(8)
Antiviral Agents
(8)
Carbamates
(8)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Effects of food and antacids on the pharmacokinetics of eltrombopag in healthy adult subjects: Two single-dose, open-label, randomized-sequence, crossover studies

Assessment of the Pharmacokinetic Interaction between Eltrombopag and Lopinavir-Ritonavir in Healthy Adult Subjects

Modeling and Simulation Support Eltrombopag Dosing in Pediatric Patients With Immune Thrombocytopenia

Effect of Hepatic or Renal Impairment on Eltrombopag Pharmacokinetics

Modeling and Simulation Support Eltrombopag Dosing in Thrombocytopenic Patients with Chronic HCV Infection

Population PK/PD Modeling of Eltrombopag in Healthy Volunteers and Patients With Immune Thrombocytopenic Purpura and Optimization of Response-Guided Dosing

Effect of Antacids and Ranitidine on the Single-Dose Pharmacokinetics of Fosamprenavir

Fosamprenavir plus Ritonavir Increases Plasma Ketoconazole and Ritonavir Exposure, while Amprenavir Exposure Remains Unchanged

Ritonavir Increases Plasma Amprenavir (APV) Exposure to a Similar Extent when Coadministered with either Fosamprenavir or APV

Novel 4,4-Disubstituted Piperidine-Based C–C Chemokine Receptor-5 Inhibitors with High Potency against Human Immunodeficiency Virus-1 and an Improved human Ether-a-go-go Related Gene (hERG) Profile

Coadministration of esomeprazole with fosamprenavir has no impact on steady-state plasma amprenavir pharmacokinetics

A Phase 1 Study To Evaluate Safety and Pharmacokinetics following Administration of Single and Multiple Doses of the Antistaphylococcal Lysin LSVT-1701 in Healthy Adult Subjects

A Randomized, Open-Label, 5-Period, Balanced Crossover Study to Evaluate the Relative Bioavailability of Eltrombopag Powder for Oral Suspension (PfOS) and Tablet Formulations and the Effect of a High-Calcium Meal on Eltrombopag Pharmacokinetics When Administered With or 2 Hours Before or After PfOS

Phase I Safety and Pharmacokinetic Trials of 1263W94, a Novel Oral Anti-Human Cytomegalovirus Agent, in Healthy and Human Immunodeficiency Virus-Infected Subjects

Phase I Dose Escalation Trial Evaluating the Pharmacokinetics, Anti-Human Cytomegalovirus (HCMV) Activity, and Safety of 1263W94 in Human Immunodeficiency Virus-Infected Men with Asymptomatic HCMV Shedding

Fosamprenavir : Clinical pharmacokinetics and drug interactions of the amprenavir prodrug

Six-Week Randomized Controlled Trial To Compare the Tolerabilities, Pharmacokinetics, and Antiviral Activities of GW433908 and Amprenavir in Human Immunodeficiency Virus Type 1-Infected Patients

Pharmacokinetic and Safety Evaluation of High-Dose Combinations of Fosamprenavir and Ritonavir

A 42-Week Open-Label Study to Assess the Pharmacokinetics, Antiretroviral Activity, and Safety of Amprenavir or Amprenavir plus Ritonavir in Combination with Abacavir and Lamivudine for Treatment of HIV-Infected Patients

Fosamprenavir/ritonavir in advanced HIV disease (TRIAD): a randomized study of high-dose, dual-boosted or standard dose fosamprenavir/ritonavir in HIV-1-infected patients with antiretroviral resistance

Pharmacokinetics and safety of GW433908 and ritonavir, with and without efavirenz, in healthy volunteers

Pharmacokinetics and Pharmacodynamics of Methadone Enantiomers After Coadministration with Amprenavir in Opioid-Dependent Subjects

Reports of Committees

Suchergebnisse filtern